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PolypharmacologyWeestablish structure activity relationships of extracellular nucleosides and nucleotides at G protein-coupled re-
ceptors (GPCRs), e.g. adenosine receptors (ARs) and P2Y receptors (P2YRs), respectively.We synthesize selective
agents for use as pharmacological probes and potential therapeutic agents (e.g. A3AR agonists for neuropathic
pain). Detailed structural information derived from the X-ray crystallographic structures within these families
enables the design of novel ligands, guides modiﬁcation of known agonists and antagonists, and helps predict
polypharmacology. Structureswere recently reported for the P2Y12 receptor (P2Y12R), an anti-thrombotic target.
Comparison of agonist-bound and antagonist-bound P2Y12R indicates unprecedented structural plasticity in the
outer portions of the transmembrane (TM) domains and the extracellular loops. Nonphosphate-containing li-
gands of the P2YRs, such as the selective P2Y14R antagonist PPTN, are desired for bioavailability and increased
stability. Also, A2AAR structures are effectively applied to homology modeling of closely related A1AR and
A3AR, which are not yet crystallized. Conformational constraint of normally ﬂexible ribose with bicyclic
analogues increased the ligand selectivity. Comparison of rigid A3AR agonist congeners allows the exploration
of interaction of speciﬁc regions of the nucleoside analogueswith the target and off-target GPCRs, such as biogen-
ic amine receptors. Molecular modeling predicts plasticity of the A3AR at TM2 to accommodate highly rigidiﬁed
ligands. Novel ﬂuorescent derivatives of high afﬁnity GPCR ligands are useful tool compounds for characteriza-
tion of receptors and their oligomeric assemblies. Fluorescent probes are useful for characterization of GPCRs
in living cells by ﬂow cytometry and other methods. Thus, 3D knowledge of receptor binding and activation
facilitates drug discovery.
Jacobson et al. Published by Elsevier B.V. on behalf of the Research Network of Computational and Structural
Biotechnology. This is an open access article under the CC BY license
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A vast biology is associated with action at the G protein-coupled
adenosine receptors (ARs) and P2Y receptors and at ionotropic P2X re-
ceptors, which ismodulated by all of the nucleoside and nucleotide pro-
cessing enzymes and transporters. This extensive signaling system is
qualiﬁed to be considered part of the ‘purinome’ [1], a term already ap-
plied in the context of the N3200 proteins that utilize purine cofactors,
including intracellular kinases [2], as well as to describe the actions of
extracellular and intracellular purines (and pyrimidines) in this collec-
tion of related receptors and enzymes.
The release of ATP, UTP and other nucleotides by various routes from
cells results in a temporal sequence of activation of these three families
of cell surface receptors [3]. The receptors activated initially are the fast
P2X ion channels (ATP-responsive trimeric channels composed of seven
distinct subunits) and some of the metabotropic P2Y receptors (i.e.
P2Y2, P2Y4 and P2Y11Rs that respond fully to nucleoside 5′-triphos-
phates and P2Y14R that responds to UDP-sugars). Upon the sequential
action of ectonucleotidases CD39 (ectonucleoside triphosphate
diphosphohydrolase 1, ENTPD1) and CD73 (ecto-5′-nucleotidase, 5′-
NT) [4], different sets of receptors are activated (i.e. P2Y1, P2Y6, P2Y12,
P2Y13 and P2Y14Rs that respond to nucleoside 5′-diphosphates), follow-
ed by the activation of four AR subtypes (A1, A2A, A2B and A3ARs), which
are not appreciably activated by any endogenous nucleotides. Naturally
occurring dinucleotides, such as Up4A, are also known to activate vari-
ous P2YRs [5].
A current challenge tomedicinal chemists is to identify selective P2R
agonist and antagonist ligands, which remains an unmet need for most
of the P2XRs and many of the P2YRs. The effort to design purine recep-
tor ligands is now aided by representative X-ray crystallographic struc-
tures in each of the three classes: A2AAR, P2Y12R and P2X4R [6–11].
Many more receptor structures in complex with different ligands will
be needed to gain a detailed and broad knowledge of molecular recog-
nition within these families. The high resolution G protein-coupled re-
ceptor (GPCR) structures and, to a lesser extent, homology models
obtained so far have proven valuable for in silico screening campaigns
[12,13]. Biophysical mapping of binding sites, lipophilic hotspots, ex-
plicit water networks and other techniques based on GPCR structures
are nowused for drug design [14]. Moro and coworkers validated a gen-
eral pharmacophore hypothesis for the human A2AAR using an external
test set of 29 newly synthesized antagonists [15]. Thus, we and others
have demonstrated the predictive power of GPCR homology modeling
and the value of applying newly determined X-ray structures to theme-
dicinal chemistry of purine and pyrimidine GPCRs [11–16]. However,
we are only at the beginning of exploring ligand design based on
GPCR X-ray structures, and we are far away from predicting selectivity
and function of ligands from such models.
In general, we establish detailed structure activity relationships in
the purine receptor families, in order to provide selective agents as
pharmacological probes and potential therapeutic agents. Our efforts
to discover novel, selective ligands for purine receptors stem initially
from the guidance and inspiration of John W. Daly, Ph.D. (1933–2008),
a noted medicinal chemist and pharmacologist. He was one of those
who deﬁned the existence of receptors for adenosine and the biological
effects of methylxanthines, by chemical and pharmacological means
[17]. He emerged from the era in which many medicinal chemistswere not yet accustomed to the idea of structure activity relationship
(SAR), in which different functionality on a given molecule subserves
distinct roles in receptor recognition. However, very early in the devel-
opment of our ﬁeld, Daly applied SAR analysis to the ARs to help deﬁne
three of the four receptor subtypes and introduced important ligand
tools, such as A1AR-selective N6-cycloalkyladenosines and 8-aryl- and
8-cycloalkyl-1,3-dipropylxanthines (with postdoctoral fellows R. F.
Bruns and M. T. Shamim) [18,19]. Much of our study of the SAR of
P2YRs has been in collaboration with T. Kendall Harden.
2. X-ray Structures of A2A and P2Y12 ReceptorsWith Bound Agonists
and Antagonists
2.1. Molecular Recognition at Adenosine Receptor Structures
The structure of adenosine consists of two chemically and
conformationally distinct moieties, each of which is associated with
separate roles in the AR orthosteric binding site(s). These two moieties
can be divided into message (ribose) vs. address (adenine) portions.
While adenine and similar ﬂat, hydrophobic heterocycles often behave
as AR antagonists, the addition of a ribose moiety at the appropriate po-
sition (adenine-9-ribosides or xanthine-7-ribosides) can confer the
ability to activate the receptor, i.e. deliver the message by complemen-
tarity with the conformation of the AR protein required to induce its
activation.
In some cases, the same substituents of the N6 and C2 positions of an
isolated adenine AR antagonist maintain the same receptor subtype
binding preferences that are found in riboside-bearing agonists (see
A1 and A3AR ligands 1–10 in Table 1), suggesting a commonmode of re-
ceptor binding. The afﬁnity of the AR agonists is generally much greater
than the corresponding adenines, because the ribose anchors and stabi-
lizes the bound ligand. Although the AR subtype selectivity of the lone
nucleobases hasmuch commonalitywith the SAR of adenosine agonists,
it is not identical [20–24]. For example, in a study of 2-, 6- and 8-
substituted adenines, Klotz et al. [22] noted a pharmacological similarity
between C2 substitution in adenosine and 8-substitution in adenine. No
AR structures containing an unmodiﬁed adenine antagonist have been
determined yet, but the positions of other AR antagonists in crystal
structures so far indicate a similar hydrophobic binding region (either
a close overlay of a 1,2,4-triazolo[1,5-a][1,3,5]triazine with the adenine
of agonists or non-superimposed rings for xanthines) [6,25]. π–π Stack-
ing of the nucleobase rings with a conserved Phe in extracellular loop
(EL)2 and often H-bonding with a conserved Asn (6.55, using
Ballesteros–Weinstein numbering [26]) are typically common to ago-
nists and antagonists in the A2AAR structures and in models of the
other AR subtypes.
Because the ribose moiety constitutes the message portion of aden-
osine agonists, we have focused on its conformational characteristics at
the ARs and also at P2X and P2YRs. From the X-ray structure of the
human A2AAR containing a bound nucleoside (Fig. 1A) [7], we now un-
derstand that the ribose moiety ﬁts in a deep subpocket of the ARs,
where it activates the receptor by drawing hydrophilic residues in
transmembrane helices (TMs) 3 and 7 toward it, like the tightening of
a belt. The ribose of adenosine agonists is coordinated by H-bonding
to conserved residues Thr (3.36), Thr or Ser (7.42) and His (7.43) [7,
27,28]. At the same time, the binding of ribosides is driven entropically
Table 1
Representative examples of the combination of address (adenine) and message (ribose or ribose-like) moieties in nucleoside ligands of various ARs. Binding afﬁnity (Ki, nM) of corre-
sponding adenosine agonist (I) and adenine antagonist (II) derivatives at three subtypes of ARs is shown, to examine the questionwhether SAR is parallel in the two series. The selectivity
column refers to the complete nucleoside derivative (address + message). The afﬁnity was measured for this study, using standard radioligand binding assays. The species is human un-
less noted (r, rat).
Selectivity I. Address + message (with ribose) II. Address (lacking ribose) References
A1AR 1, CPA 2 [24,44]
A2AAR 3, PEA 4 [21,23]
Mixed 5 6 [23,71]
A3AR 7,MRS3558 8,MRS5930 [20]
A3AR 9,MRS5698 10,MRS5923 [28]
288 K.A. Jacobson et al. / Computational and Structural Biotechnology Journal 13 (2015) 286–298by the displacement of unstable water molecules in this region.
Departure of unstable water molecules also can contribute to the bind-
ing of AR antagonists [14,29]. Although it lacks a G protein or G protein
mimic, the agonist-bound A2AAR structure by Xu et al. [7] displays
intracellular features that resemble other activated GPCR struc-
tures. This complex contains a bound 6-(2,2-diphenylethylamino)-9-
((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-
yl)-N-(2-(3-(1-(pyridin-2-yl)piperidin-4-yl)ureido)ethyl)-9H-purine-
2-carboxamide (UK432097), a failed experimental drug for treatment of
chronic obstructive pulmonary disease. Thus, the agonist-induced con-
traction of the ribose-binding region of the A2AAR appears to be propa-
gated to the cytoplasmic side of the receptor that is in contact with the
Gs protein (as demonstrated structurally for the β2-adrenergic receptor[30]). This conformational adaptation to agonist is likely to be similar
but not identical at the other AR subtypes.
Prior to the X-ray structural determination, we sought to deﬁne the
receptor-preferred conformation of the ribose ring chemically by intro-
ducing steric constraints on the native, freely-twisting ribose moiety by
fusing two small carbocyclic rings. The methanocarba (bicyclo[3.1.0]
hexane) ring system (fused cyclopropyl and cyclopentyl rings) freezes
opposite twists of a ribose-like moiety (either (N), North or (S),
South envelope conformations) when incorporated into nucleoside/
nucleotide analogues with the bond of ring fusion at either of two
positions [31]. These modiﬁcations can enhance or reduce potency at
different subtypes of purine receptors in comparison to the ribose
moiety [31]. These ribosemodiﬁcations, applied across the entire family
Fig. 1.Agonist-bound crystallographic structures of A2AAR (PDB ID: 3QAK, bound to UK432097) [7] and P2Y12R (PDB ID: 4PXZ, bound to 2-MeSADP) [9]. Overall structure of the receptors
and details of the binding sites. Transmembrane helices are colored from blue (TM1) to red (TM7). Ligands are shown in CPK representation with colors that indicate: the nucleobase
(magenta), the ribose moiety (blue), the N6 and C2 substituents (yellow) and the phosphate groups (red).
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types, for example (N)-methanocarba at the A3AR [73]. Compounds 7
and 9 in Table 1 contain a potency- and selectivity -enhancing (N)-
methanocarba ring. The effects of an (N)-methanocarba substitution on
afﬁnity at the A1 and A2AARs is variable, depending on other substitution
of the nucleoside. Another effective means of enforcing a (N) or
(S) conformation of the ribose was the addition of a methyl group to
the 2′- or 3′-ribose carbon [32]. The X-ray structure of the agonist-
bound A2AAR conﬁrmed the presence of a (N)-ribose conformation [7].
Nevertheless, the general (N) conformation of ribose represents a range
of geometric parameters [33], and the conformational requirements for
ribosemight differ slightly between AR subtypes.Without a crystal struc-
ture of the A3AR,we lack the detail of the ribose binding region needed to
explain the greater preference of (N)-methanocarba analogues at the
A3AR compared to other AR subtypes.
Fig. 2A shows a progression of structural changes from prototypical
agonists 11–13 leading to enhanced A3AR selectivity, including (N)-
methanocarba (15–18 and 23–25) and 4′-thio (14) [34] agonists. Either
the reduction of H-bonding ability of the hydrophilic 5′-carboxamide
(including by 4′-truncation for its complete removal, 20–22 and 26–
28) or the introduction of rigidity of the ribosemoiety, as in spirolactam
19 [35], tends to convert agonists into antagonists (or at least partial
agonists) with the retention of A3AR selectivity.
Novel ﬂuorescent derivatives of high afﬁnity GPCR ligands are useful
tool compounds for characterization of receptors and their oligomeric
assemblies. Fluorescent probes are useful for characterization of GPCRs
in living cells by microscopy or ﬂow cytometry or in cell membranes.
Fluorescent agonists but not antagonists are highly internalized, consis-
tent with the general phenomenon of agonist-induced GPCR internali-
zation. A (N)-methanocarba modiﬁcation together with a 2-ethynyl
group was incorporated in a highly selective A3AR agonist ﬂuorescent
probe, MRS5218 18 (KD 31 nM), which was useful for ﬂow cytometry
of whole cells expressing the A3AR [36]. This probe contains an amide-
linked Cy5 (cyanine) ﬂuorophore.
2.2. Molecular Recognition at P2YR Structures
In collaboration with Ray Stevens, Qiang Zhao, Christa Müller and
colleagues [8,9], we analyzed the X-ray structure of the human P2Y12R
(the ﬁrst high resolution structure of any P2YR), an important anti-
thrombotic target that is the site of action of three drugs already on
the market. Three compounds used clinically: two irreversibly binding
thienopyridines (clopidogrel and prasugrel), which are actually
prodrugs of reactive thiols, and one reversible nucleotide-like antago-
nist, actually a nucleoside (tigcagrelor) [37]. The P2YRs belong on theδ-branch of GPCRs, which has only one other known structure for com-
parison, i.e. PAR1, another platelet receptor [38]. The antagonist-bound
crystal structure of P2Y12R contained an experimental non-nucleotide
antagonist from Astra Zeneca, AZD1283 29 (Fig. 3), an ethyl 6-
aminonicotinate sulfonylurea [8,39]. A benzyl moiety on AZD1283 dis-
places outwardly the position of TM6 with respect to the agonist-
bound P2Y12R structure (Figs. 1B and 3A) [9]. Several unusual features
of the P2Y12R were noted, including a bifurcated binding pocket
(Fig. 3B) and an extended and linear TM5. TM5 in most Family A
GPCRs has a proline, which is associatedwith a kink in the helical struc-
ture. The extension and linearity of TM5 leads to the previously termed
conserved disulﬁde bridge between TM3 and EL2 to be undeﬁned in the
AZD1283 structure and likely cleaved. Thus, it appears that this disulﬁde
is dynamic in P2Y12R andmay not be essential for the overall integrity of
the receptor structure.
Also, the structures of P2Y12R complexes with a bound agonist
2-methylthioadenosine 5′-diphosphate (2-MeSADP 30) and a bound
partial agonist (2-MeSATP) were determined [9]. The ﬁrst antagonists
identiﬁed for this receptor were nucleotides (2-MeSATP and other
ATP derivatives), but it appears that some of these have agonist proper-
ties [40], which is consistent with the close overlay of 2-MeSATP with
2-MeSADP in the receptor structures. The only binding feature in com-
mon between AZD1283 and the nucleotides is π–π stacking of Tyr105
(3.33) with aromatic rings, a cyanopyridine and adenine, respectively.
A comparison of nucleotide-bound and nonnucleotide-bound com-
plexes of the P2Y12R illustrates unprecedented divergence of structure
for stable complexes of the same receptor. The negatively charged nu-
cleotide ligands are surrounded by at least 7 cationic residues in the
loop regions and the outer portions of the helices, which are highly pos-
itively charged. This draws the ELs and the top portions toward the nu-
cleotide ligands, which are almost completely enclosed. The phosphate
moiety of 30 is coordinated by cationic and H-bonding residues in the
N-terminal segment (through water molecules), in TMs 3, 6 and 7 and
in EL2. It is to be noted that this agonist-bound P2Y12R structure does
not display typical intracellular features of activated GPCR structures,
so it is considered an inactive state of the receptor. Nevertheless, the li-
gand binding pocket and the extracellular regions are informative
concerning conformational adaptation of the structure to accommodate
nucleotides. There are ﬁve other pairs of GPCRs in agonist-bound and
antagonist-bound states [41], and the P2Y12R shows the greatest diver-
gence of all these paired structures.
A cartoon representing the progressive opening of the P2Y12R struc-
ture depending on the nature of the bound ligand is shown in Zhang
et al. [9], with the nucleotide agonists (closed) and the nonnucleotide
antagonists (open) as the extremes. The nonnucleotide antagonist
AB
Fig. 2. Progression of structural changes in adenosine derivatives leading to enhanced A3AR selectivity [27,28,35,36,43]. Binding Ki values at the human A3AR using 12 as radioligand are
given in italics (nM). A. Successive structural changes leading to hypermodiﬁed (N)-methanocarba analogues. 4′-Truncation was performed in the ribose, thioribose and
(N)-methanocarba series with the general observation that afﬁnity but not efﬁcacy at the A3ARwasmaintained. A3AR antagonist 19was shown to be useful in lowering interocular pres-
sure in glaucoma models [35]. Compounds 12 (nonselective) and 22 (A3AR-selective) are useful high afﬁnity radioligands for routine binding assays. Compounds 16 and 21 are demon-
strated to be useful radioligands for positron emission tomography (PET) [74]. B. Extension of the C2 position with rigid arylethynyl substituents.
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which consequently is free of the steric constraints of the loops that
are drawn toward the negatively-charged ligands. Some of the
nucleotide-mimetic antagonists, such as Cangrelor [42], are predicted
to bindwith a similar conformation to 30while other bulkier antagonist
derivatives do not dock readily into the 2-MeSADP or 2-MeSATP com-
plexes, because the binding site is too contracted. Thus, a possible dis-
placement of parts of the TM region is proposed in order to ﬁt these
antagonists. We are currently modeling binding at the P2Y12R toestablish energetically favorable dockingmodes of other known ligands,
both agonists and antagonists.
The divergence of the A2AAR and P2Y12R structures emphasize
that these are two very different receptor classes. In the nucleo-
side and nucleotide-bound structures of these two receptors, re-
spectively, the adenosine moiety is ﬂipped (Fig. 1). Thus, in the
P2Y12R, the adenine base, not the ribose occupies a deeper por-
tion of the binding site, which now has a hydrophobic character
[7,9].
Fig. 3. A. A comparison of nucleotide agonist-bound and non-nucleotide antagonist bound P2Y12R structures [8,9]. The binding site contracted on the extracellular side of the TMs in the
P2Y12R–2MeSADP 30 structure (green) in comparison to the complexwith antagonist AZD1283 29 (purple, PDB ID: 4NTJ). Only one nonnucleotide–P2Y12R complex has been determined
so far; it is not known if this structure generalizes for other nonnucleotide antagonists. B. Side view of the superposed nucleotide agonist-bound and non-nucleotide antagonist-bound
P2Y12R structures with surfaces showing the binding site shape. The P2Y12R–2MeSADP structure is shown in green ribbons with the associated binding site surface in cyan. The
P2Y12R–AZD1283 structure is shown inmagenta ribbonswith the associated binding site surface in pink. The two subpockets of the bifurcated binding pocket are indicated as 1 (principle
location of both ligands) and 2.
291K.A. Jacobson et al. / Computational and Structural Biotechnology Journal 13 (2015) 286–2983. Structure-based Design of Novel A1, A2A and A3 Adenosine
Receptor Agonists
3.1. Design of Ligands Based on the X-ray Structures
For the structure-based design of new AR nucleoside ligands, each
portion of the adenosine molecule requires a different approach for de-
rivatization; no single approach is general for all applications. A2AAR
crystallographic structures are effectively applied to homology model-
ing of the closely related A1AR and A3AR, which are not yet crystallized.
Based on the X-ray structure of the A2AAR [7], the C2 position is located
in an approach path that easily frees itself from the constraints of thepharmacophore binding region to exit the receptor. This opening to
the extracellular medium explains why the elongation of chains at the
C2 position, for example by peptide or polymeric moieties, was found
empirically to be allowed in receptor binding. The N6 region is slightly
more constrained spatially than the C2. We have probed the tight ﬁt
of various hydrophobic N6 substituents at the ARs, thus explaining the
early observations concerning stereochemistry at the α-carbon, for ex-
ample that R-N6-(phenylisopropyl)adenosine (R-PIA) is more potent
at ARs than S-PIA [17,43].
The 5′ position of AR agonists is unique in that it is situated in a
small, partly hydrophilic region. There are no charged residues in this
small subpocket, therefore attempts to introduce charged groups on
292 K.A. Jacobson et al. / Computational and Structural Biotechnology Journal 13 (2015) 286–298the 5′moiety were mostly unsuccessful. In silico fragment screening by
Katritch and coworkers identiﬁed high scoring hits, of which we were
able to synthesize 23 molecules [16]. Nearly all of the uncharged syn-
thetic hits, including some novel 5′-amides that were not previously
envisioned as AR ligands, bound to the A2AAR with micromolar afﬁnity
or better. Some of the hits were greatly enhanced in A1AR afﬁnity,
which was explained structurally.
3.2. A Novel A1 Agonist for Suppression of Seizures
More detail about the ﬁt of a novel selective A1AR agonist in the N6
region is shown using small cycloalkyl rings on this substituent. We
chose the 4′-truncated (N)-methanocarba series because of its com-
pactness, steric constraint, and increased hydrophobicity for the design
of novel A1AR agonists, and incorporated many hydrophobic N6Fig. 4. Representative data from a study of polypharmacology of otherwise selective AR ligands.
or in one case to the A1AR [43] and that were subjected to binding and structural analysis of off-
truncated compounds 7–10 in Table 1. Orange ﬂash arrows indicate the position of truncation. B
analysis by docking to antagonist-bound receptor structures are shown [20]. Left side: adenines
carbons) and 10 (yellow carbons) and adenosine derivative 9 (orange carbons) at the α2C recesubstituents that were known to be A1AR-enhancing in the ribose se-
ries. The only substituent that maintained A1AR selectivity and full efﬁ-
cacy in this truncated series was the dicyclopropylmethyl group [43].
This A1AR-selectivity in the truncated 2-chloro-(N)-methanocarba se-
ries was not general across all enhancing N6 groups identiﬁed in the
riboside series; for example, the 4′-truncated equivalent of A1AR agonist
2-chloro-N6-cyclopentyladenosine (CCPA 31, structure not shown) was
not A1AR-selective. In fact, a tight ﬁt of theN6 group in the outer portion
of the receptor surrounding the exocyclic amine seemed to be impor-
tant for potency and efﬁcacy, especially in the 4′-truncated series to
compensate for the missing anchoring effect of the ribose 5′-region.
Thus, MRS5474 37 (Fig. 4A), bearing a N6-dicyclopropylmethyl group,
is a structural sweet spot with respect to the SAR in this series, because
of its balance of full agonism andmodest selectivity at the human A1AR
(Ki 47.9 nM).A. Shown are six of the rigid congeners that are known to bind selectively to the A3AR [20]
target sites, includingmanyGPCRs. Four other rigid congeners were included in this study:
. As an example, binding afﬁnity at threeGi-coupledα2 adrenergic receptors and structural
8 (cyan carbons) and 10 (yellow carbons) at theα2B receptor; right side: adenines 8 (cyan
ptor.
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MRS5474 37 (smaller size, fewer H-bonding donors and acceptors,
less polar surface area) with respect to the prototypical A1AR agonists,
such as CPA 1 and CCPA 31, would alter its in vivo activity, especially ac-
tivity in the brain. Use of an A1AR agonist to control seizures has long
been a goal of CNS research in the purinergic ﬁeld, but progress has
been hampered by the toxicity associated with the other agonists [45].
However, MRS5474 37 was found to reduce electrically-induced sei-
zures in the 6 Hz minimal clonic seizure test in mice without the usual
toxicity of A1AR agonists. In fact, a maximum tolerated dose (MTD)
study in mice of this agonist revealed that doses up to 60 mg/kg (40-
fold higher than the effective anti-seizure dose inmice) were not lethal.
3.3. A Rationally Designed A2A Agonist for Irreversible Inhibition of the
Receptor
Irreversibly binding ligands of GPCRs are useful as pharmacological
tool compounds and in some cases as therapeutic agents.Wewondered
if we could rationally design a chemically reactive agonist based on the
position of a reactive groupwhen the ligandwasdocked to theA2AARX-
ray structure. A series of active ester derivatives 38–40was synthesized,
in which a reactive o-nitro ester was incorporated on an elongated C2
chain (Fig. 5) [46]. The ester was intended to acylate a nucleophilic
amino group in the extracellular regions of the receptor. This is also a
useful structural probe, because the role of the ELs in receptor binding
and activation is not entirely clear. The ELs are highly ﬂexible regions
of most GPCRs, and perhaps plasticity of these regions could induce or
otherwise alter the activation of the receptor. Even though the business
surface of the receptor for contacting the G protein (cytosolic sides of
TMs 3, 5 and 6) or arrestin (cytosolic sides of TMs 1, 2 and 7)was clearly
distinct from the ELs [41], conformational effects from the ELs could be
propagated along the length of the helices to the intracellular side.
Mutagenesis results indicated that the irreversible loss of receptor
binding induced by acetyl ester MRS5854 38 was dependent on theFig. 5.Targeted covalentmodiﬁcation of theA2AAR: Tethering of a reactive group to reach a dista
of K153, but not K150 (both circled). Bmax values are in pmol/mg protein [46].presence of Lys153, but not Lys150 (both of which are in the region of
EL2 where the active ester is predicted to be located). The amino
group of Lys153 is predicted to lie closer to the reactive carbonyl of
MRS5854 than Lys150 (Fig. 5). Thus, we have designed a chemically
reactive agonist ligand based on structural insights.
3.4. Design of Highly Speciﬁc A3 Agonists Can Be Interpreted Structurally
Some reports have detected dose-dependent activity of the proto-
typical agonists of the A3AR, such as 11 and 13, at other AR subtypes
in vivo [47]. Thus, there is a need for the introduction of more highly se-
lective A3AR agonists. The SAR of (N)-methanocarba nucleosides acting
at the A3AR was explored, resulting in consistently high afﬁnity and se-
lectivity at the A3AR upon combination with favorable N6 groups, such
as methyl or substituted benzyl, and a rigid C2-arylethynyl substituent.
The combination of these substituents provides a general class of highly
speciﬁc agonists, in which the A3AR is consistently in the nM range and
the afﬁnity at other AR subtypes is almost always N10 μM. One example
that had a Ki value of 3 nMat both human andmouseA3ARs,MRS5698 9
(Fig. 2B), contains diﬂuoro substitution of the terminal phenyl ring
intended to reduce oxidative metabolism in vivo [27].
In order to accommodate such rigid C2 substituents and maintain
other conserved interactions of ribose and adenine with the receptor
(Fig. 6),we usedmolecularmodeling of theA3AR to propose anoutward
movement of TM2. This proposed receptor plasticity is not an arbitrary
rearrangement; rather it is based on similarity to several other active-
like state structures of GPCRs. Thus, a hybrid homologymodel was con-
structed, which was based on the active state of the A2AAR with respect
to TMs 1 and 3–7 and on the active state of rhodopsin, i.e. opsin, with re-
spect to TM2. The doubly extended biaryl derivative MRS5679 25 re-
quired an outward movement of TM2 by ~7 Å. The reason that a
similar rearrangement of TM2 cannot occur in the A2AAR is that there
are a total of 3 disulﬁde bridges that further constrain the movement
on the outer loop region of the receptor.l site. Irreversible loss of receptor binding byMRS5854 38was associatedwith thepresence
Fig. 6. Predicted outwardmovement of TM2 of A3AR to accommodate a rigid aryl ethynyl extension at the adenine C2 position (example shown for a biaryl derivative, selective full agonist
MRS5679 25 in cyan). A hybrid A3ARmodel containing TM2based on the opsin structurewas required for docking. The other TMswere based on theA2AAR agonist bound structure [7,27].
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membranes, because of a permanent negative charge at physiological
pH. In 1994, we attempted empirically to introduce a sulfonate on the
prototypical riboside analogues, such as IB-MECA 11. The effort failed;
introduction of an m- or p-sulfonate group on the N6-benzyl group
and greatly reduced the afﬁnity at the rA3AR — from the nM to the μM
level. Instead, we recently used a structure-based approach to design a
pharmacological probe to distinguish central and peripheral effects
of A3AR agonists [28]. Selectivity of N3000-fold at both the human
and mouse A3ARs was achieved with m-sulfophenyl analogue 23
(MRS5841, Fig. 2B), but a sulfonate in the p-position 24 produced a po-
tent and selective mixed agonist of A1 and A3ARs. Thus, there is a strong
dependence of the afﬁnity on distal interactions between the ligand and
the EL regions of the receptor, and we predicted speciﬁc interactions
with polar and hydrophobic residues based on ligand docking to homol-
ogy models of the human and mouse A3ARs.
3.5. Polypharmacology of AR Ligands
The analysis of off-target activities of new drug candidates is an es-
sential component of drug discovery. With the design of rigid nucleo-
side congeners that bind to the ARs and now the availability of many
GPCR structures, we have used this as a test case to quantify and possi-
bly predict the likelihood of speciﬁc off-target (non-AR-related) activi-
ties in a systematic approach. In some cases these activities would be
considered undesirable and would have to be eliminated, and other
off-target activities that might synergize with the desired AR activity
could be accentuated.
We analyzed the polypharmacology of otherwise ‘selective’ A3AR li-
gands at off-target GPCRs and other receptors [20]. Increased conforma-
tional rigidity of A3AR agonists and adenine antagonists allows the
exploration of interaction of speciﬁc regions of the ligands with other
GPCRs that have structural information (either by direct X-ray determina-
tion or bymolecularmodeling), such as biogenic amine receptors. A series
of highly rigidiﬁed congeners (7–10, 32–37) was assembled for probing
off-target effects experimentally and correlating these ﬁndings with
GPCR structures (Fig. 4). The ten compounds submitted to the Psychoac-
tive Drug Screening Program (PDSP) at the University of North Carolina
are indicated, and Ki values of binding hits (deﬁned as N50% inhibitionat 10 μMin the single point screen)were determined. The structural anal-
ysis was conducted at various GPCRs that turned up as hits in the screen.
We present here the example ofα2 adrenergic receptors, although a sim-
ilar analysis was performed at β-adrenergic, serotonergic receptors and
other GPCRs. The patterns of off-target binding often correlatedwith spe-
ciﬁc moieties on the molecules, which were predicted to be essential for
binding at those receptors using molecular docking. As predicted, when
theN6-benzyl group (viewed as a deep anchor in theα2 adrenergic recep-
tors) was omitted in subsequent analogues, this off-target activity disap-
peared. The conserved Asp (3.32) that serves as the counterion for
biogenic amines in their GPCRs, changed to a H-bonding role in the pre-
dicted recognition of adenosine congeners at the same receptors.
3.6. A3 Agonists for Inﬂammatory Diseases, Cancer and Chronic
Neuropathic Pain
The action of A3AR agonists in diseasemodels is pleiotropic [48], and
diverse therapeutic applications are envisioned. Can-Fite Biopharmahas
advanced IB-MECA 11 to Phase 2 and 3 clinical trials for autoimmune in-
ﬂammatory diseases, including psoriasis and rheumatoid arthritis, A3AR
agonists effectively reduce tumor size in several animal models [49],
and Cl-IB-MECA 13 has progressed to Phase 2 clinical trials for hepato-
cellular carcinoma [50]. Also, an imidazoquinolinamine allosteric
enhancer of the A3AR [51] is being proposed for treatment of inﬂamma-
tory diseases by Can-Fite.
The mechanisms involved in the actions of A3AR agonists in disease
models have been summarized by Fishman et al. [49]. In cancer and in-
ﬂammation, the A3AR is upregulated in the affected tissue. This patho-
logical level of receptor expression, which can often be determined by
measuring the A3AR level in peripheral blood mononuclear cells, is
also predictive of a patient's response to an A3AR agonist. Activation of
the A3AR appears to correct imbalances in the downstream signaling
pathways leading to changes in transcription in the nucleus. In models
of in vivo inﬂammation, A3AR agonists have an anti-inﬂammatory effect
by reducing activation of NF-κB (in synoviocytes, neutrophils and other
immune cells), in part by reducing the expression of TNF-α.
In cancer, an A3AR-agonist-induced decrease in expression or activity
of NF-κB could reduce its antiapoptotic effect. Activation of the A3AR also
corrects an imbalance in the Wnt signaling pathway. cAMP inhibition
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tion) of the serine/threonine kinase GSK-3β. The resulting increased
phosphorylation of β-catenin allows it to be removed from the cyto-
plasm by ubiquitination, and its reduced action in the nucleus leads to
suppression of cyclin D1 and c-myc and consequently cell growth inhibi-
tion. Effects of A3AR activation on downstream signaling can also be in
opposite directions. For example, its myeloprotective effect is accompa-
nied by increased NF-κB in splenocytes.
Together with collaborator Daniela Salvemini, we have demonstrat-
ed that A3AR agonists, including prototypical and novel ligands that are
highly selective for this receptor subtype, are effective in suppressing
and preventing chronic neuropathic pain [52]. The chronic constriction
injury (CCI) model of neuropathic pain in mice was used to screen
dozens of analogues in vivo. The prototypical A3AR agonist IB-MECA
and the hypermodiﬁed MRS5698 9were both highly potent and efﬁca-
cious in this model when administered intraperitoneally or orally, with
effective doseswell below1 mg/kg in themouse. There are both periph-
eral and central components to this action, as indicated using the
nonpermeant MRS5841 23 [28]. Both reversal of mechanoallodynia
and hyperalgesia were observed. The necessity for A3AR agonism was
demonstrated using the selective AR antagonists and A3AR−/− mice.
The potency of A3AR agonists was greater than other pain medications.
Also, A3AR agonists do not develop analgesic tolerance [53].
4. Novel P2Y Receptor Ligands
There has beenmuch recent progress in the design of selective P2YR
ligands [42,54–60]. For example, BMS and Pﬁzer have reported diaryl
urea derivatives as potent and selective nonnucleotide antagonists of
the P2Y1R, a target for new antithrombotic drugs [58,59]. Nevertheless,
there is still a large need for improved P2YR ligands of increased stabil-
ity and bioavailability. Most of the P2YR agonists are still labile phos-
phate derivatives. Fischer et al. have demonstrated that introduction
of a boranophosphate at the α-phosphate position of P2YR agonists
greatly enhances the in vivo stability [60]. Other methods of increasing
the stability of phosphate groups with varying success include
methylenephosphonate bridges and thiophosphates. There is a need
for additional uncharged and drug-like P2Y ligands, and the hope is
that structure-based approaches will solve this need in the future.
In an effort to understand the conformational factors in recognition of
P2YR ligands, we applied the steric constraints of the (N)-methanocarba
modiﬁcation of ribose in nucleotide agonists (and P2Y1R antagonists)
to the eight subtypes of P2Y receptors [31,42]. In most cases, the
(S)-methanocarba ring was introduced for comparison. This effectively
deﬁned the conformational preference at each of the P2Y1-like Gq
coupled receptors, but uncertainty remains about which rigid ring
would maintain afﬁnity at the P2Y12-like Gi-coupled receptors.
Among P2Y1-like Gq-coupled receptors, most receptors prefer the
(N)-methanocarba modiﬁcation over the (S). The potency of ATP at the
hP2Y1R was enhanced 29-fold compared to native ATP by this
(N) bicyclic ribose substitution [72]. At the hP2Y2 and hP2Y11Rs, (N)-
methanocarba-ATP was roughly equipotent to ATP. (S)-methanocarba-
ATP (racemic) was 5- and 44-fold less potent than ATP at the P2Y1 and
P2Y2Rs, respectively. (N)-methanocarba-UTP was ~2-fold less potent
than UTP at the P2Y2 and P2Y4Rs. Only the UDP-responsive Gq-coupled
P2Y6R prefers the (S)-conformation of ribose; the preference is so strong
that the (N)-methanocarba UDP analogue is completely inactive, while
the (S)-methanocarba UDP analogue is 7-fold more potent than UDP.
Thus, the identical ribose conformational preference is not maintained
throughout the evolution of the P2YR family.
4.1. P2Y6 Agonists for Diabetes and Fluorescent P2Y6 Agonists
The protective effects of activation of P2Y6R against TNF-αwere ﬁrst
shown in P2YR-expressing astrocytoma cells. P2Y6R activation protects
pancreatic islet cells from apoptosis and stimulates glucose-dependentinsulin release [61,62] and in insulin target tissues increases glucose up-
take (unpublished). These actions involve the enzyme 5′-AMP-activated
protein kinase (AMPK), a metabolic regulator that is a target for treat-
ment of type 2 diabetes. We have used a potent and somewhat (12-
fold vs. P2Y2R) selective P2Y6R dinucleotide agonist P1-(uridine 5′-)-
P3-(N4-methoxycytidine 5′-)triphosphate (MRS2957, 41, structure not
shown),which ismore stable thanmost simple UDP analogues to the ac-
tion of ectonucleotidases. InMIN6 β-islet cells, treatment withMRS2957
(500 nM) activated AMPK, whichwas blocked by P2Y6R-selective antag-
onist N,N″-1,4-butanediyl-bis-[N′-(3-isothiocyanatophenyl)]thiourea
(MRS2578). Also, MRS2957 induced phosphorylation of acetylcoenzyme
A carboxylase (ACC), a marker of AMPK activity [61]. We attenuated
P2Y6R-mediated AMPK phosphorylation pharmacologically to reveal in-
volvement of intracellular Ca2+pathways. P2Y6R agonist induced insulin
secretion at high glucose, which was also reduced by AMPK siRNA. The
pharmacological agents used to block key steps in the P2Y6R-induced
signaling cascade were: calcium chelator BAPTA-AM, calmodulin-
dependent protein kinase kinase (CaMKK) inhibitor STO-069 and IP3 re-
ceptor antagonist 2-APB. In insulin target cells (C2C12 skeletal muscle
cells and 3T3-L1 adipocytes), MRS2957 signiﬁcantly increased glucose
uptake compared to control, which was antagonized by MRS2578.
MRS2957-treatment resulted in signiﬁcant phosphorylation of AMPK in
both cell lines, which was abolished by pre-incubation with MRS2578.
Also, MRS2957 (30 min incubation) increased glucose transporter
GLUT4 recruitment to the cell membrane (unpublished), which was
blocked byMRS2578 or AMPK inhibitor (Compound C). Our results indi-
cate that the P2Y6R is involved in controlling glucosemetabolism atmul-
tiple levels, and this may be mediated through AMPK signaling.
P2Y6R activation by UDP was identiﬁed as an autocrine process
by which insulin secretion is potentiated in response to glucose [63].
Nevertheless, the use of P2Y6R agonists for the treatment of diabetes
is not yet a practical concept for pharmaceutical development. There
are detrimental effects of P2Y6R receptor activation, such as increased
interleukin (IL) 6 and other inﬂammatory mediators in the lung and
elsewhere [64], vasoconstriction [65] and promotion of osteoclast for-
mation in bone [66]. Moreover, all of the known P2Y6R agonist ligands
are nucleotide derivatives and therefore of low oral bioavailability.
We designed ﬂuorescent conjugates of functionalized congeners that
display high P2YR afﬁnity, for characterization of these GPCRs in living
cells by ﬂow cytometry and in cell membranes. Fluorescent agonists are
mostly internalized consistent with agonist-induced GPCR internaliza-
tion, and this labeling is attenuated by speciﬁc P2YR ligands. Examples
are 5′-diphosphate derivative MRS4129 42 [54] and MRS4162 43 [55]
(Fig. 7A), which are ﬂuorescent pyrimidine nucleotides, respectively, se-
lective agonist of the P2Y6R (EC50 9 nM, phospholipase C activation)
andhigh afﬁnity pan-agonist at P2Y2R, P2Y4R and P2Y6R (expressed in as-
trocytoma cells). At the end of the 60min incubation periodwith astrocy-
toma cells expressing the P2Y6R, the fraction of ﬂuorescence of MRS4129
associated with the internalized label was much greater (77% of the total
binding) than the fraction on the cell surface (17% of the total binding).
The point of chain extension from which to tether the ﬂuorophore
was a 4-alkyloxoimino group on the pyrimidine ring. This group pre-
serves the double bond character of the 4 substituent of the nucleobase,
which favors receptor recognition by analogy to the 4-carbonyl group of
uracil. A previous attempt to extend substituents through a pyrimidine
4-thioether failed to maintain P2YR activity (e.g. a 4-hexylthio-UDP
equivalent was 10-fold less potent than UDP at the P2Y6R) [67]. In
both cases, the ﬂuorophores were conjugated by [2 + 3] click cycload-
dition chemistry between an alkynyl group on the pharmacophore
and an azide on the ﬂuorophore (AlexaFluor488 for MRS4129 and
BODIPY for MRS4162).
4.2. Receptor Docking and Chemical Modiﬁcation of a P2Y14 Antagonist
Both UDP-glucose (UDPG) and UDP are cognate agonists of the
Gi-coupled P2Y14R [68]. In collaborationwithHarden, Vsevolod Katritch
Fig. 7. A. Fluorescent agonist ligands 42 and 43 (as salts) with high afﬁnity, variably, for P2Y2R, P2Y4R and P2Y6R [54,55]. The colors range from the charged phosphate (brown) to the
green nucleoside moiety, to the spacer (blue) and the ﬂuorophore (violet). B. High afﬁnity P2Y14R ﬂuorescent antagonist ligand 45 (Ki = 80 pM, antagonist activity measured in
hP2Y14R-expressing CHO cells) [70] in comparison with its structural lead PPTN 44 (as HCl salt). The colors indicate the pharmacophore (black), a spacer (blue) and the ﬂuorophore
(green).
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on potent and highly selective 4-((piperidin-4-yl)-phenyl)-(7-(4-
(triﬂuoromethyl)-phenyl)-2)-naphthoic acid (PPTN 44, KB = 0.434 nM
in antagonizing the cAMP effects of UDPG) [57], which was originally
reported by Merck [56]. Unfortunately, PPTN displays low oral bioavail-
ability, and additional P2Y14 antagonistswill be needed. The lack of effect
up to 10 μM PPTN at the other Gq-linked P2YRs was shown [57]. At Gi-
coupled P2YRs, there was no inhibitory effect of PPTN up to 1 μM. This
2-naphthoic acid derivative inhibited UDPG-promoted chemotaxis in
HL-60 cells and in human neutrophils, suggesting application of such an-
tagonists in inﬂammation. Activation of the P2Y13R and the P2Y14R in
mast cells promotes degranulation, suggesting application of P2Y antag-
onists for the treatment of asthma [69].
We designed the ﬁrst ﬂuorescent ligand of the P2Y14R, i.e. the
AlexaFluor488-labeled antagonist MRS4174 45 (Fig. 7B) [70]. This com-
pound contained a functionalized chain at the secondary nitrogen of the
piperidine ring, a site that was chosen based on ligand docking at a
P2Y14R homology model. An azide-bearing ﬂuorophore was conjugated
to an alkyne-functionalized antagonist intermediate by [2 + 3] click
cycloaddition chemistry. We modeled the hP2Y14R based on the recent
2-MeSADP-bound hP2Y12R X-ray structure and simulated antagonist
docking, which suggested that the piperidine N of PPTN is accessible for
tethering ﬂuorophores. Click chemistrywas used to conjugate functional-
ized PPTN alkyne derivatives and azide-bearing ﬂuorophores. Flow
cytometry showed high speciﬁc P2Y14R binding of MRS4174 45 with
exceptionally high afﬁnity (Ki 80 pM, in antagonizing UDPG-induced
cAMP inhibition in P2Y14R-expressing CHO cells). Known P2Y ligands
inhibited cell labeling consistently with afﬁnity order. Thus, the utility of
MRS4174 has been validated initially, but additional methods optimiza-
tion will be needed to utilize this compound in a routine assay.5. Conclusions
Numerous therapeutic concepts are associatedwith selectivemodu-
lation of ARs and P2YRs. We used chemical synthesis and molecular
modeling based on X-ray structures to explore novel ligand discovery
at adenosine receptors and P2Y receptors. X-ray structures of agonist-
bound and antagonist-bound P2Y12R establish binding modes and de-
tect conformational changes involved in activation, especially in the ex-
tracellular loop region. Thus, the 3D knowledge of receptor binding and
activation is facilitating drug discovery at GPCRs that respond to extra-
cellular nucleosides and nucleotides. However, its use as a primary
tool in predicting the pharmacological proﬁle of proposed new ligands
is not yet realized. Future X-ray structures to reveal the structures of
other receptors or the already crystallized receptor with novel ligands
and the development of more systematic in silico methods will be
required.
The ARs are well established as medicinal chemical targets with
many selective agonists and antagonists. A3AR agonists have proven
more beneﬁcial in disease models (such as autoimmune inﬂammatory
diseases and cancer) than A3AR antagonists. The A3AR selectivity of pro-
totypical agonists has been improvedusing a structure-baseddesign ap-
proach. A constrained ribose substitution in theNorth (N) conformation
enhances A3AR afﬁnity and selectivity, which leads to a general class of
highly speciﬁc agonists. Off-target activitywas probed structurally. Con-
formational plasticity of the A3AR is predicted to accommodate rigid C2
extension, leading to C2 arylethynyl analogueMRS5698, which protects
against chronic neuropathic pain. At the antiepileptic A1AR, a compact,
truncated selective agonist MRS5474 that does not produce the toxicity
associated with prototypical A1AR agonists is suggested for reducing
seizures. With the multiplicity of effects and sites of distribution of the
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tion of antithrombotic P2Y12R antagonists) is still more exploratory.
P2Y6R agonists have beneﬁcial effects in the pancreas and in insulin tar-
get tissues, suggestive of possible application to diabetes. We reported
the ﬁrst ﬂuorescent ligand of a P2Y receptor: MRS4129, which is selec-
tive and potent nucleotide agonist of the P2Y6R. Fluorescent agonists
MRS5218 (A3AR), MRS4129 and MRS4162 (P2Y6R and other subtypes)
and ﬂuorescent antagonist MRS4174 (P2Y14R) are useful probes to
characterize speciﬁc receptors expressed in living cells using ﬂow
cytometry and other methods.
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